BACKGROUND: Whether elevations in levels of urinary biomarkers of tubular injury (urine neutrophil gelatinase-associated lipocalin [NGAL] and kidney injury molecule 1 [KIM-1]) are associated with future risk of kidney disease has not been investigated. STUDY DESIGN: 1:1 nested case-control study. SETTING & PARTICIPANTS: 686 participants in the Multi-Ethnic Study of Atherosclerosis (MESA). PREDICTOR: NGAL and KIM-1 were measured at baseline, expressed as log-transformed continuous variables, and categorized into deciles. OUTCOMES: Kidney function was estimated by cystatin C level using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. Incident CKD stage 3 was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) and an eGFR decrease >1 mL/min/1.73 m(2) per year, and rapid kidney function decrease was defined as decrease ≥3 mL/min/1.73 m(2) per year. MEASUREMENTS: Cases were defined as persons with eGFR >60 mL/min/1.73 m(2) who subsequently developed incident CKD stage 3 and/or had rapid kidney function decrease by the MESA year-5 visit. Controls were matched for age, sex, race, diabetes, and baseline eGFR. We adjusted for age, hypertension, and presence of albuminuria (albumin-creatinine ratio ≥30 mg/g). RESULTS: Of 343 cases, 145 had incident CKD stage 3, 141 had rapid kidney function decrease, and 57 had both. Mean eGFR for controls was 81 ± 10 mL/min/1.73 m(2) at baseline and 80 ± 10 mL/min/1.73 m(2) at follow-up compared with 82 ± 13 and 58 ± 10 mL/min/1.73 m(2) for cases. Each doubling of KIM-1 level (in picograms per milliliter) was associated with an OR of 1.15 (95% CI, 1.02-1.29) for incident CKD stage 3 and/or rapid kidney function decrease. Compared with the lowest 90%, the highest decile of KIM-1 level was associated with an OR of 2.02 (95% CI, 1.15-3.56) for the outcome; these associations were independent of albuminuria. NGAL levels (in nanograms per milliliter) were not associated with incident CKD stage 3 and/or rapid kidney function decrease (OR, 1.04; 95% CI, 0.99-1.10). Results were similar when KIM-1 and NGAL levels were standardized for urine creatinine. LIMITATIONS: The case-control design limits the ability to account for persons who died or were not available for follow-up. CONCLUSIONS: Urinary KIM-1 level is associated with future risk of kidney disease independent of albuminuria. Urinary biomarkers of tubular injury are a promising tool for identifying persons at risk of CKD.
BACKGROUND: Whether elevations in levels of urinary biomarkers of tubular injury (urine neutrophil gelatinase-associated lipocalin [NGAL] and kidney injury molecule 1 [KIM-1]) are associated with future risk of kidney disease has not been investigated. STUDY DESIGN: 1:1 nested case-control study. SETTING & PARTICIPANTS: 686 participants in the Multi-Ethnic Study of Atherosclerosis (MESA). PREDICTOR: NGAL and KIM-1 were measured at baseline, expressed as log-transformed continuous variables, and categorized into deciles. OUTCOMES: Kidney function was estimated by cystatin C level using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation. Incident CKD stage 3 was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m(2) and an eGFR decrease >1 mL/min/1.73 m(2) per year, and rapid kidney function decrease was defined as decrease ≥3 mL/min/1.73 m(2) per year. MEASUREMENTS: Cases were defined as persons with eGFR >60 mL/min/1.73 m(2) who subsequently developed incident CKD stage 3 and/or had rapid kidney function decrease by the MESA year-5 visit. Controls were matched for age, sex, race, diabetes, and baseline eGFR. We adjusted for age, hypertension, and presence of albuminuria (albumin-creatinine ratio ≥30 mg/g). RESULTS: Of 343 cases, 145 had incident CKD stage 3, 141 had rapid kidney function decrease, and 57 had both. Mean eGFR for controls was 81 ± 10 mL/min/1.73 m(2) at baseline and 80 ± 10 mL/min/1.73 m(2) at follow-up compared with 82 ± 13 and 58 ± 10 mL/min/1.73 m(2) for cases. Each doubling of KIM-1 level (in picograms per milliliter) was associated with an OR of 1.15 (95% CI, 1.02-1.29) for incident CKD stage 3 and/or rapid kidney function decrease. Compared with the lowest 90%, the highest decile of KIM-1 level was associated with an OR of 2.02 (95% CI, 1.15-3.56) for the outcome; these associations were independent of albuminuria. NGAL levels (in nanograms per milliliter) were not associated with incident CKD stage 3 and/or rapid kidney function decrease (OR, 1.04; 95% CI, 0.99-1.10). Results were similar when KIM-1 and NGAL levels were standardized for urine creatinine. LIMITATIONS: The case-control design limits the ability to account for persons who died or were not available for follow-up. CONCLUSIONS: Urinary KIM-1 level is associated with future risk of kidney disease independent of albuminuria. Urinary biomarkers of tubular injury are a promising tool for identifying persons at risk of CKD.
Authors: Kiyoshi Mori; H Thomas Lee; Dana Rapoport; Ian R Drexler; Kirk Foster; Jun Yang; Kai M Schmidt-Ott; Xia Chen; Jau Yi Li; Stacey Weiss; Jaya Mishra; Faisal H Cheema; Glenn Markowitz; Takayoshi Suganami; Kazutomo Sawai; Masashi Mukoyama; Cheryl Kunis; Vivette D'Agati; Prasad Devarajan; Jonathan Barasch Journal: J Clin Invest Date: 2005-03 Impact factor: 14.808
Authors: Caroline S Fox; Martin G Larson; Eric P Leip; Bruce Culleton; Peter W F Wilson; Daniel Levy Journal: JAMA Date: 2004-02-18 Impact factor: 56.272
Authors: Todd H Driver; Ronit Katz; Joachim H Ix; Jared W Magnani; Carmen A Peralta; Chirag R Parikh; Linda Fried; Anne B Newman; Stephen B Kritchevsky; Mark J Sarnak; Michael G Shlipak Journal: Am J Kidney Dis Date: 2014-03-18 Impact factor: 8.860
Authors: Simon B Ascher; Rebecca Scherzer; Michelle M Estrella; Michael G Shlipak; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael R Bennett; Chirag R Parikh; Joachim H Ix; Vasantha Jotwani Journal: Am J Nephrol Date: 2019-09-25 Impact factor: 3.754
Authors: Leonard Goldenstein; Todd H Driver; Linda F Fried; Dena E Rifkin; Kushang V Patel; Robert H Yenchek; Tamara B Harris; Stephen B Kritchevsky; Anne B Newman; Mark J Sarnak; Michael G Shlipak; Joachim H Ix Journal: Am J Kidney Dis Date: 2014-06-18 Impact factor: 8.860
Authors: Sushrut S Waikar; Venkata Sabbisetti; Johan Ärnlöv; Axel C Carlsson; Josef Coresh; Harold I Feldman; Meredith C Foster; Gudeta D Fufaa; Johanna Helmersson-Karlqvist; Chi-Yuan Hsu; Paul L Kimmel; Anders Larsson; Yumin Liu; Lars Lind; Kathleen D Liu; Theodore E Mifflin; Robert G Nelson; Ulf Risérus; Ramachandran S Vasan; Dawei Xie; Xiaoming Zhang; Joseph V Bonventre Journal: Nephrol Dial Transplant Date: 2016-06-07 Impact factor: 5.992
Authors: Kathleen D Liu; Wei Yang; Alan S Go; Amanda H Anderson; Harold I Feldman; Michael J Fischer; Jiang He; Radhakrishna R Kallem; John W Kusek; Stephen R Master; Edgar R Miller; Sylvia E Rosas; Susan Steigerwalt; Kaixiang Tao; Matthew R Weir; Chi-Yuan Hsu Journal: Am J Kidney Dis Date: 2014-10-11 Impact factor: 8.860
Authors: William R Zhang; Timothy E Craven; Rakesh Malhotra; Alfred K Cheung; Michel Chonchol; Paul Drawz; Mark J Sarnak; Chirag R Parikh; Michael G Shlipak; Joachim H Ix Journal: Ann Intern Med Date: 2018-10-23 Impact factor: 25.391
Authors: Ahmad Kaddourah; Stuart L Goldstein; Rajit Basu; Edwards J Nehus; Tara C Terrell; Lori Brunner; Michael R Bennett; Christopher Haffner; John L Jefferies Journal: Pediatr Nephrol Date: 2016-05-02 Impact factor: 3.714